Intervention
Etoposide
ClinicalTrials.gov intervention label
Clinical trials
60 shownA Study of YL201 in Combination With Serplulimab in Participants With Treatment-naïve Extensive-stage Small Cell Lung CancerNCT07739758 · 2026-08-18
RECRUITINGLow-dose Thoracic Radiotherapy Followed by Adebrelimab Plus Chemotherapy, and Then Sequential Maintenance Therapy With Adebrelimab for Extensive-stage Small Cell Lung CancerNCT07583550 · 2026-07-20
RECRUITINGA Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cancer(PANKU-Lung07)NCT07502300 · 2026-06-15
RECRUITINGA Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)NCT07227597 · 2026-01-29
RECRUITINGA Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung CancerNCT07155174 · 2025-11-25
RECRUITINGUsing Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM StudyNCT06769126 · 2025-11-06
RECRUITINGA Study of Ivonescimab in First-Line ES-SCLCNCT07245446 · 2025-10-29
RECRUITINGA Phase Ib Clinical Study on the Safety and Efficacy of HC010 Combined With Chemotherapy in Lung CancerNCT07381829 · 2025-10-27
RECRUITINGSintilimab Combined With Tafolecimab and Chemotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung CancerNCT07061535 · 2025-07-30
RECRUITINGA Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).NCT06646276 · 2025-02-25
RECRUITINGSafety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung CancerNCT06712355 · 2025-02-03
RECRUITINGPhase II Study of Ivonescimab and Cadonilimab in Combination with Chemotherapy in Patients with ES-SCLCNCT06769971 · 2025-02-01
RECRUITINGAtezolizumab and Rechallenge Chemotherapy in Relapsed Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC).NCT06663098 · 2025-01-24
RECRUITINGMaintenance Lurbinectedin in Combination With Serplulimab for Patients With ES-SCLCNCT06497530 · 2024-12-01
RECRUITINGA Study of Lower Radiotherapy Dose to Treat Children With CNS GerminomaNCT06368817 · 2024-10-22
RECRUITINGAdebrelimab Plus Apatinib and Etoposide for the Treatment of HER2-Negative Breast Cancer Brain MetastasisNCT06418594 · 2024-10-10
RECRUITINGA Study on the Efficacy of Atezolizumab Combined with ChemotherapyNCT06780826 · 2024-08-28
RECRUITINGAdebrelimab Plus Apatinib for Maintenance Therapy of Extensive Stage Small Cell Lung CancerNCT06480864 · 2024-08-09
RECRUITINGTislelizumab Combined With Chemotherapy and Thoracic Radiotherapy in ES-SCLCNCT06536868 · 2024-08-01
RECRUITINGA Study of Adebrelimab Combined With Apatinib Mesylate and Chemotherapy for Neoadjuvant Therapy and Biomarker Analysis in Limited-stage Small Cell Lung CancerNCT06483282 · 2024-06-21
RECRUITINGSupraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA StudyNCT06039371 · 2024-05-21
RECRUITINGPhase I/II Trial in ES-SCLC to Enhance Response to Atezolizumab Plus Chemotherapy With Total Body IrradiationNCT06110572 · 2024-04-24
RECRUITINGSafety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLCNCT06217757 · 2024-04-18
RECRUITINGNeoadjuvant Therapy With Toripalimab and JS004 Combined With Etoposide and Platinum Chemotherapy for Limited-stage Small Cell Lung Cancer : A Phase 2 TrialNCT06256237 · 2024-04-01
RECRUITINGTeniposide, Cisplatin and Serplulimab for Treatment of ES-SCLC, a Randomized Controlled StudyNCT07583511 · 2024-02-01
RECRUITINGIN10018 Combination Therapy in Treatment-naïve ES-SCLCNCT06030258 · 2023-10-30
RECRUITINGMOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung CancerNCT05903092 · 2023-09-26
RECRUITINGTesting the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung CancerNCT05624996 · 2023-07-12
RECRUITINGPomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated LymphomasNCT05389423 · 2023-06-27
RECRUITINGDose Attenuated Chemotherapy in Compromised Patients With Lung CancerNCT05800587 · 2023-02-22
RECRUITINGDurvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)NCT05068232 · 2022-08-19
RECRUITINGLamivudine in Combination With Chemoimmunotherapy for the Treatment of Extensive Stage Small Cell Lung CancerNCT04696575 · 2021-07-02
RECRUITINGA Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic LymphomaNCT04139304 · 2021-05-24
RECRUITINGA Study Comparing QLC5508 in Combination With QL2107 Versus Tislelizumab Plus Platinum-based Chemotherapy in Participants Wih Treatment-naïve Extensive-Stage Small Cell Lung CancerNCT07802821 · 2026-10-15
NOT_YET_RECRUITINGA Study to Test Obrixtamig in Combination With Pumitamig in People With Advanced Small Cell Lung Cancer (Dareon®-Rosetta35)NCT07843940 · 2026-10-05
NOT_YET_RECRUITINGBenmelstobart Plus Anlotinib, Chemotherapy and Thoracic Radiation for Limited-Stage Small Cell Lung CancerNCT07538258 · 2026-04-20
NOT_YET_RECRUITINGA Study of Benmelstobart, Anlotinib, Chemotherapy and Thoracic Radiotherapy for People With Extensive-stage Small Cell Lung CancerNCT07538271 · 2026-04-20
NOT_YET_RECRUITINGIparomlimab and Tuvonralimab Injection Combined With Chemotherapy and Sequential Thoracic Radiotherapy for Extensive-Stage Small Cell Lung CancerNCT07349225 · 2026-01-31
NOT_YET_RECRUITINGA Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)NCT07005128 · 2025-08-18
ACTIVE_NOT_RECRUITINGToripalimab Combined With Chemotherapy as Adjuvant Therapy for Incidental Small Cell Lung Cancer After Radical Resection of Lung Cancer: A Single-Center, Randomized Controlled Clinical Study Protocol Number: LungMate-033NCT07097948 · 2025-08-01
NOT_YET_RECRUITINGBenmelstobart, Anlotinib and Chemotherapy as First-line Treatment for Extensive-stage Small-cell Lung CancerNCT06931145 · 2025-04-15
NOT_YET_RECRUITINGDisitamab Vedotin in Combination with Metronomic Chemotherapy in Advanced HER2-expressing Breast Cancer.NCT06857747 · 2025-03-01
UNKNOWNLow-dose Radiotherapy Combined With Concurrent Chemotherapy, Toripalimab and Tifcemalimab in the Treatment of ES-SCLCNCT06732258 · 2025-01-10
WITHDRAWNToripalimab and JS004 Combined With Platinum-based Chemotherapy for Relapsed and Extensive-stage Small Cell Lung CancerNCT06648200 · 2024-11-01
NOT_YET_RECRUITINGA Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological FeaturesNCT06564844 · 2024-10-15
ACTIVE_NOT_RECRUITINGSafety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With ChemotherapyNCT06449209 · 2024-08-05
ACTIVE_NOT_RECRUITINGPhase 1b/2 Study of LDRT in Combination With AK104 Plus Chemotherapy as First-line Treatment for ES-SCLCNCT06477523 · 2024-05-16
ACTIVE_NOT_RECRUITINGDAREONᵀᴹ-8: A Study to Test How Well Different Doses of BI 764532 in Addition to Standard of Care Are Tolerated by People With Advanced Small Cell Lung CancerNCT06077500 · 2024-02-14
ACTIVE_NOT_RECRUITINGPembrolizumab After Radiation Therapy and Chemotherapy in Limited Stage Small Cell Lung CancerNCT06140407 · 2024-02-14
TERMINATEDA Phase Ⅱ Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy for Extensive-Stage Oligometastatic SCLCNCT06177925 · 2023-12-10
UNKNOWNHypofractionated Radiation Therapy After Durvalumab and Chemotherapy for the Treatment of Stage IV Extensive Stage Small Cell Lung Cancer, CASPIAN-RT TrialNCT05161533 · 2023-10-19
WITHDRAWNA Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLCNCT05844150 · 2023-06-01
ACTIVE_NOT_RECRUITINGDebio 0123 in Combination With Carboplatin and Etoposide in Adult Participants With Small Cell Lung Cancer That Recurred or Progressed After Previous Standard Platinum-Based TherapyNCT05815160 · 2023-05-02
TERMINATEDStudy of Low-Dose Radiotherapy Concurrent Chemotherapy With Serplulimab for Patients With ES-SCLCNCT05765825 · 2023-03-07
ACTIVE_NOT_RECRUITINGJS004 Combined With Toripalimab and With Standard Chemotherapy Treat Patients With Advanced Lung CancerNCT05664971 · 2023-02-09
COMPLETEDStudy of Pembrolizumab, Lenvatinib and Chemotherapy Combination in First Line Extensive-stage Small Cell Lung CancerNCT05384015 · 2022-11-07
ACTIVE_NOT_RECRUITINGStudy of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLCNCT05595460 · 2022-10-10
ACTIVE_NOT_RECRUITINGFirst-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)NCT05361395 · 2022-08-24
ACTIVE_NOT_RECRUITINGA Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and AtezolizumabNCT05142696 · 2022-07-13
ACTIVE_NOT_RECRUITINGSafety and Efficacy Study of First-line Treatment With QL1706 Plus Chemotherapy in Extensive-Stage Small Cell Lung CancerNCT05309629 · 2022-04-18
COMPLETEDCommon conditions
Small Cell Lung Cancer25Lung Cancer14Non-small Cell Lung Cancer13Small Cell Lung Carcinoma13Small-cell Lung Cancer13Extensive-Stage Small-Cell Lung Cancer12Extensive-Stage Small Cell Lung Cancer11Extensive Stage Lung Small Cell Carcinoma10Prostate Cancer6Small Cell Lung Cancer Extensive Stage6Breast Cancer5Extensive Stage Small Cell Lung Cancer5Stage III Lung Cancer AJCC v85Extensive Stage Small Cell Lung Carcinoma4Plasmablastic Lymphoma4SCLC4SCLC, Extensive Stage4Small Cell Lung Cancer Limited Stage4Ann Arbor Stage II Diffuse Large B-Cell Lymphoma3Ann Arbor Stage III Diffuse Large B-Cell Lymphoma3Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma3HIV Infection3HIV Infections3Non Small Cell Lung Cancer3Stage IIIA Lung Cancer AJCC v83
Leading sponsors
National Cancer Institute (NCI)18AstraZeneca8Hoffmann-La Roche7M.D. Anderson Cancer Center7Merck Sharp & Dohme LLC7Bristol-Myers Squibb6Shanghai Pulmonary Hospital, Shanghai, China5Sichuan University5Radiation Therapy Oncology Group4AbbVie3Amgen3BioNTech SE3Celgene3Chinese Academy of Medical Sciences3Eli Lilly and Company3
Trial status mix
COMPLETED68
ACTIVE_NOT_RECRUITING35
TERMINATED34
RECRUITING33
UNKNOWN20
NOT_YET_RECRUITING8
WITHDRAWN6
Phase mix
PHASE2126
PHASE160
PHASE337
NA4
PHASE42
EARLY_PHASE11
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.